Review Article
Apathy following Bilateral Deep Brain Stimulation of Subthalamic Nucleus in Parkinson’s Disease: A Meta-Analysis
Table 1
Characteristics of the eligible studies.
| | Number | Author | N | Age | Disease duration | DBS programming | State in the evaluation | Scale | Follow-up | Preoperative score | Preoperative LEDD | Postoperative score | Postoperative LEDD |
| | 1 | Houvenaghel et al. [21] | 26 | 56.6 ± 7.4 | 11.47 ± 4.54 | Bilateral STN-DBS | Drug on and stimuli on | AES | 3 months | 31.8 ± 7.0 | 1271.2 ± 555.6 | 31.2 ± 7.7 | 758.0 ± 407.79 | | 2 | Robert et al. [20] | 44 | 56.3 ± 7.5 | 11.4 ± 4.1 | Bilateral STN-DBS | Drug on and stimuli on | AES | 3 months | 31.4 ± 6.4 | 1280.8 ± 632.4 | 31.6 ± 7.1 | 889.9 ± 209.3 | | 3 | Lewis et al. [17] | 27 | 61.1 ± 9.1 | 12.7 ± 6.7 | Bilateral STN-DBS | Drug on and stimuli on | AES | 1 year | 34.04 ± 9.58 | 831.5 ± 425.91 | 37.44 ± 8.71 | 359.23 ± 264.46 | | 4 | Lewis et al. [18] | 28 | 61.1 ± 8.9 | 12.43 ± 6.74 | Bilateral STN-DBS | Drug on and stimuli on | AES | 1 year | 33.85 ± 9.71 | 832 ± 426 | 37.0 ± 8.91 | 359.3 ± 264.5 | | 5 | Lhommee et al. [16] | 67 | 57.8 ± 7.2 | 10.5 ± 3.1 | Bilateral STN-DBS | Drug on and stimuli on | SAS | 1 year | 6.2 ± 3.5 | 1026 ± 459 | 9.4 ± 4.5 | 284 ± 312 | | 6 | Chou et al. [19] | 10 | 62.1 ± 6.5 | 9.1 ± 5.8 | Bilateral STN-DBS | Drug on and stimuli on | SAS | 6 months | 13.2 ± 8.6 | 1164.9 ± 752.9 | 13.6 ± 7.4 | 567.9 ± 512.4 | | 7 | Drapier et al. [15] | 17 | 56.9 ± 8.7 | 11.8 ± 2.6 | Bilateral STN-DBS | Drug on and stimuli on | AES | 3 months | 37.2 ± 5.5 | - | 42.5 ± 8.9 | - | | 8 | Castelli et al. [14] | 19 | 62.1 ± 4.2 | 14.7 ± 5.0 | Bilateral STN-DBS | Drug on and stimuli on | SAS | 17 months | 11.6 ± 4.1 | 1192.5 ± 415.7 | 12.6 ± 5.3 | 571.6 ± 274.8 | | 9 | Drapier et al. [13] | 15 | 59.7 ± 7.6 | 12.2 ± 2.8 | Bilateral STN-DBS | Drug on and stimuli on | SAS | 6 months | 13.0 ± 6.5 | 1448 ± 400 | 18.8 ± 9.7 | 1127 ± 482 |
|
|
AES: Apathy Evaluation Scale; SAS: Starkstein Apathy Scale.
|
